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Flow-based enzymatic synthesis of melatonin
and other high value tryptamine derivatives:
a ﬁve-minute intensiﬁed process†
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Francesco Molinari b and Francesca Paradisi *a,d
To increase the uptake of biocatalytic processes by industry, it is
essential to demonstrate the reliability of enzyme-based methodo-
logies directly applied to the production of high value products.
Here, a unique, eﬃcient, and sustainable enzymatic platform for
the multi-gram synthesis of melatonin, projected to generate
around 1.5 billion U.S. dollars worldwide by 2021, and its ana-
logues was developed. The system exploits the covalent immobiliz-
ation of MsAcT (transferase from Mycobacterium smegmatis) onto
agarose beads increasing the robustness and longevity of the
immobilized biocatalyst. The fully-automated process deriving
from the integration between biocatalysis and ﬂow chemistry is
designed to maximize the overall yields (58–92%) and reduce reac-
tion times (5 min), overcoming the limitation often associated with
bioprocesses and bridging the gap between lab scale and industrial
production.
Melatonin (N-acetyl-5-methoxytryptamine) is a natural mam-
malian hormone that plays a crucial role in regulating the
human body’s circadian sleep-wake cycle.1 Clinically, it exhi-
bits positive eﬀects as a sleep aid2,3 and a powerful antioxidant
as an over-the-counter dietary supplement.4 Recent studies on
tryptamine derivative redox activity show their involvement to
re-establish the equilibrium between pro- and antioxidants.
Additionally, the fact that melatonin readily crosses the blood–
brain-barrier suggests that it could be an adjuvant in treating
oxidative stress, a key factor of neurodegenerative disorders.5
Thanks to its antiestrogenic properties as well as its ability to
improve the eﬃcacy and reduce the side eﬀects of convention-
al antioestrogens, melatonin can be safely associated with
breast cancer therapies currently in use.6 The first source of
commercially available melatonin was the animal pineal
glands.7 However, a major drawback encountered during the
extraction process was contamination from animal tissue.
Recently, a microbial cell factory approach for the preparation
of recombinant melatonin in Saccharomyces cerevisiae was
reported,8 but the engineered yeast strain produced melatonin
only in very low concentration (15 mg L−1), following four enzy-
matic steps in a 76 h fermentation process. Consequently, mel-
atonin and its analogues are almost exclusively chemically syn-
thesized. Industrial procedures involve a final step where tryp-
tamines are acetylated with acetic acid anhydride or acetyl
chloride in anhydrous environment,9,10 at low temperature11
and using bases to carry out the reaction.9–11 Although these
reagents are inexpensive, their environmental toxicity and
hygroscopicity reduce their appeal in greener protocols; more-
over, due to their high and non-specific reactivity, low selecti-
vity is often observed in the acetylation of amines bearing
other reacting functional groups.12 Alternatively, amide bonds
can be formed by using heterogeneous and homogeneous
metal catalysts, which are often expensive and need further
purification steps.13 A green chemistry perspective on catalytic
amide bond formation was recently assessed, pointing out that
biocatalysis is among the techniques better suited to achieve
sustainable processes for amide formation.14 Within this
framework, the further development of biocatalysis in bio-
degradable, unconventional reaction media such as deep
eutectic solvents (DESs) has been reported.15,16 Some hydro-
lases, for example, have proven to be eﬀective in catalyzing
amidation of esters in DESs.17 Following more traditional
methodologies, amide synthesis was achieved in DESs with
Pd/C without further purification steps.18 An acetyltransferase
from Mycobacterium smegmatis (MsAcT) was proposed as bioca-
talyst for the synthesis of amides starting from primary amines
and short-chain esters in water.19,20 MsAcT was initially discov-
ered and fully characterized for its ability to transfer acetyl
group to alcohols.21,22 A very interesting feature of MsAcT is its
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remarkable activity even at high substrate concentrations.23 De
facto, biocatalysis can be considered a reliable tool for organic
and industrial chemists only if selectivity and mild operational
conditions (typical of biotransformations) meet green and
intensified processes, characterized by high product concen-
tration and favourable atom economy.
Integration of biocatalytic methods and continuous flow
reactors (either micro- or meso-reactors) is designed to inten-
sify the overall process and to overcome low productivity,
which is one of the more common limitation of biocatalysis.24
In this work, we have developed a unique, rapid, and robust
enzymatic method to prepare melatonin and analogous
amides using immobilized MsAcT in a flow reactor to set-up
highly productive biotransformations on a multi-gram scale.
Firstly, a highly tailored immobilization of the octameric
MsAcT, key to achieve a robust and durable catalyst, was devel-
oped. To date, MsAct has been immobilized onto carbon nano-
tubes to fulfil its perhydrolase activity,25 and siliceous mono-
lithic microreactors have been used for the acetylation of neo-
pentylglycol.26 Although continuous-flow microchannel reac-
tors can be eﬃcient, the synthesis and functionalization of
silica monoliths is anything but eco-friendly (e.g., requirement
of HNO3, high temperature, inert atmosphere, long reaction
times). In the present study, strategies forming covalent bonds
between the matrix and the enzyme (see ESI†) were screened
to achieve a durable catalyst to be used specifically at high flow
rate for scalable productivity.27,28 Hydrophilic carriers (i.e.,
agarose, cellulose, 3-aminopropylic silica, epoxy resins) with
diﬀerent pore diameter (40–60/10–20 nm) and spacer size were
chosen. Hydrophobic supports have been avoided as they can
create non-specific interactions between the enzyme and non-
functionalized hydrophobic regions of the carrier.25 Diﬀerent
concentration of MsAcT were tested (1, 2, and 5 mg gmatrix
−1)
for each carrier; the highest recovered activity (73%), was
obtained at low enzyme concentration using activated glyoxyl
agarose as support (see ESI†). This can be explained taking
into consideration that MsAcT is a large molecule (72 × 72 ×
60 Å) which needs tight association of dimer pairs to work.
The supports showing the best retained activity (>30%) were
examined before and after enzyme immobilization by scanning
electron microscopy (SEM) to detect any surface change
(see ESI†). In Fig. 1, the characterization of the agarose
matrix is reported. Particles supported with 1 mgMsAcT gmatrix
−1
did not present any aggregation phenomena, thus maximizing
the contact area during the biotransformation. While epoxy
resins seem to have the same behavior, SEM analysis of
cellulose demonstrates that the fibers create aggregates with
less surface available for the interaction with the substrates
(see ESI†).
Additionally, spatial distribution of fluorophore-labelled
enzyme was investigated (see ESI†). MsAcT is localized across
the porous surface of the agarose beads favoring an intimate
contact with the substrates (Fig. 2). The spatial enzyme organ-
ization remained stable after two-week storage demonstrating
that the enzyme is covalently bound to the matrix and unable
to migrate.
Batch reactions to test the catalytic performance of agarose
immobilized MsAcT were carried out. Three amines (2-phenyl-
ethylamine, p-ethylaniline, 3,4-dimethoxybenzylamine),
already studied using the free MsAcT, were selected.20 The
reaction was carried out in phosphate buﬀer (0.1 M pH 8.0)
using non-activated acyl donors (ethyl formate, ethyl acetate,
ethyl propionate) and activated esters (vinyl acetate, vinyl pro-
pionate). The substrate concentration was fixed at 0.25 M
(>30 g L−1), while 10% v/v (∼1 M) of acyl donor was used,
observing maximum conversions between 75 and 100% in
times ranging between 30 min and 2 h (see ESI†). It is of note
that the immobilized system aﬀorded much higher activity
and substrate tolerance than the free enzyme: in fact, the
enzyme loading (0.2 mg mL−1) required for this level of reactiv-
ity was five times lower than for free MsAcT, even if a 5-fold
higher substrate concentration was used.
To demonstrate the robustness and longevity of the
immobilized biocatalyst, stability of the immobilized enzyme
towards diﬀerent esters (acting as acyl donors) and temperature
was investigated. Agarose-immobilized MsAcT showed a remark-
able increase of the tolerance to the assayed esters (more than
50% of retained activity after 24 h) and slightly higher thermal
stability when incubated up to 70 °C (see ESI†).
Despite amide formation being dramatically favored over
hydrolysis due to the characteristic hydrophobicity of the
active site, product cleavage was observed over prolonged
times; accordingly, continuous product removal can guarantee
Fig. 2 Confocal microscopy of glyoxyl agarose particles immobilizing
MsAcT (1 mg gmatrix
−1) 20× magniﬁcation.
Fig. 1 SEM images of agarose matrix. Line a: Activated glyoxyl agarose
before MsAcT immobilization 60×; 500×; 1000× magniﬁcation respect-
ively. Line b: Activated glyoxyl agarose after MsAcT immobilization (1 mg
gmatrix
−1) 60×; 500×; 1000× magniﬁcation respectively.
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high yield of the desired amide. With this in mind and taking
into consideration that flow processing has also the potential
to accelerate biotransformations (due to enhanced mass trans-
fer and better control of the reaction parameters), a continu-
ous flow reactor using immobilized MsAcT was set-up and
optimized for the preparation of N-(2-phenylethyl)acetamide
using EtOAc as acetylating agent. A segmented liquid–liquid
phase composed of buﬀer/EtOAC 90 : 10 was flowed into the
packed-bed column containing immobilized MsAcT. Keeping
constant the residence time (5 min), concentration of the
amine in the feeding flow was varied. Complete conversion
was observed using an amine feed between 0.25–0.50 M
(30–60 g L−1). When 2-phenylethylamine concentration was
increased up to 1.0 M (120 g L−1), the biphasic flow was
slightly modified to ensure a constant excess of acyl donor
(85 : 15 aqueous phase/EtOAc), allowing for N-acetylation with
90% molar conversion (Scheme 1).
Continuous product removal completely eliminated hydro-
lysis of the newly formed amide, improving the overall process
yield. The process was further implemented with the addition
of an in-line extraction. The biphasic system exiting from the
flow reactor was continuously separated using a Zaiput liquid/
liquid separator and the desired amide was recovered in the
organic phase, significantly simplifying and accelerating the
work-up procedure, as no further purification was required.
The designed process can be considered an ultra-eﬃcient,
closed-loop strategy,29 as all the materials involved in the bio-
synthesis can be reused. The recovered waste water containing
the unreacted amine can be easily re-circulated in the system,
while evaporation of the organic phase allows for the recovery
of ethyl acetate, used as acyl donor. Further optimization of
the reaction conditions (such as addressing the buﬀer formu-
lation and shifting towards more volatile mixtures) is ongoing.
The operational stability of the immobilized MsAcT under con-
tinuous flow was also assayed by running the reactor over pro-
longed time. Samples (4 mL) were collected and analyzed by
HPLC. The consistency of the results obtained over time was
verified in terms of N-(2-phenylethyl)acetamide produced,
showing excellent stability under the chosen working con-
ditions. A total volume of more than 400 mL was collected
without any loss of enzymatic activity. This allowed for an
extensive utilization of the pre-packed column with an unpre-
cedented amide production of 56 per day (using 1.6 mg of
enzyme), thus demonstrating the intensification of the process
with excellent atom eﬃciency and automation.
The established methodology was then applied to the syn-
thesis of the target pharmaceuticals; N-acetyl amines derived
from commercially available tryptamine, 5-methoxy triptamine
and serotonin (Fig. 3). Melatonin analogues, as well as playing
an important biological role as agonist of melatonin receptors,
are promising neuroprotectant drugs for the treatment of neu-
rodegenerative disorders.30,31
Using EtOAc as acetyl donor (10% v/v) and 0.5 M amine
solutions, melatonin analogues were prepared with very good
molar conversions (70%, 62% and 60% respectively) with 5-minute
residence time (further increasing the reaction time did not
give any significantly better result). Activated vinylOAc was also
employed for the N-acetylation of 0.5 M tryptamines: the
desired amides were rapidly produced (5 min of residence
time) with excellent conversion (95%, 96% and 89%, respect-
ively). Downstream liquid extraction aﬀorded products with
high chemical purity (>95%) and 90%, 92% and 85% isolated
yields, respectively. Notably, N-acetylation of tryptamines cata-
lyzed by MsAcT occurred with complete chemoselectivity,
since no reaction involving the phenolic OH was observed,
demonstrating that our process can be considered a clean,
mild and virtually zero-waste procedure for amide production.
Scheme 1 Flow synthesis of amides. Solution A: 0.5 M or 1.0 M amine
solution in phosphate buﬀer (0.1 M, pH 8.0) containing 5–10% DMSO.
Solution B: EtOAc or vinylOAc. T = 25 °C, P = atmospheric pressure.
Fig. 3 Flow production of melatonin analogues.
Table 1 Continuous preparation (24 h) of melatonin (0.5 M, 95 g L−1
feed) in ﬂow reactor. Reactor volume 1.2 mL, residence time 5 min
Acetyl donor M. c.a (%)
Space time
yield (g d−1)
Catalyst productivity
(mmol mg−1)
EtOAc 62 23.2 62
VinylOAc 96 36.9 99
aDetermined by HPLC.
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Finally, continuous flow-based preparation of melatonin
was carried out for 24 hours (Table 1), showing that multi-
gram synthesis of melatonin was achievable using less than
2 mg of enzyme in a 1.2 mL reactor: 23.2 or 36.9 g of melato-
nin were isolated after automated work up described above.
Conclusions
The high substrate concentrations (and relative yields), together
with the remarkable operational stability of the immobilized
system described in this work, help to overcome the perception
about the ineﬃciency of biocatalysis when compared with con-
ventional chemical strategies. The method described is remark-
ably intensified and can compete with conventional (bio)pro-
cesses for the production of melatonin and melatonin deriva-
tives (and more in general amides) at industrial level.
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